

SATELLITE LUNCH SYMPOSIUM You are invited!

ECR 2024 Vienna, Austria

Friday, March 1st 12.30 – 13.30 Room E1

The Future is Now: The Novel GBCA Gadopiclenol

Moderator: Carlo Catalano

Faculty

Carlo Catalano Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy

Josef Vymazal Department of Radiology, Na Homolce Hospital, Prague, Czech Republic

Ali Pirasteh Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA

Emanuel Kanal Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA **The clinical value of high relaxivity** Josef Vymazal

Implementation of Gadopiclenol as the extracellular agent for Body MRI Applications Ali Pirasteh

Experience with Gadopiclenol for MRI of the CNS

Emanuel Kanal

General description

Gadolinium-based contrast agents (GBCAs) are fundamental to many diagnostic MRI procedures. However, until recently, most purely extracellular GBCAs had similar relaxivity properties resulting in similar contrast enhancement when administered at equivalent dose. Gadopiclenol is a newly approved, highly stable GBCA with markedly increased relaxivity which permits the administered dose to be halved relative to the approved dose of most other extracellular GBCAs without loss of diagnostic performance. This symposium will address the importance of high relaxivity in clinical practice and will present early clinical experience with gadopiclenol for approved indications in the body and CNS.



